NASDAQ:SBBP - Strongbridge Biopharma Stock Price, Forecast & News

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma plc (NASDAQ:SBBP) released its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.07. The biotechnology company had revenue of $5.68 million for the quarter, compared to the consensus estimate of $5.06 million. Strongbridge Biopharma had a net margin of 211.37% and a return on equity of 45.77%. View Strongbridge Biopharma's Earnings History.

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Strongbridge Biopharma.

Strongbridge Biopharma updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$18-20 million, compared to the consensus revenue estimate of $$20.82 million.

5 brokerages have issued 1-year price targets for Strongbridge Biopharma's stock. Their forecasts range from $8.00 to $18.00. On average, they expect Strongbridge Biopharma's stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 290.9% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Press coverage about SBBP stock has been trending extremely negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Strongbridge Biopharma earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Strongbridge Biopharma.

Strongbridge Biopharma saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 393,800 shares, a decline of 24.1% from the January 15th total of 518,500 shares. Based on an average trading volume of 496,800 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.2% of the shares of the stock are sold short. View Strongbridge Biopharma's Current Options Chain.

Some companies that are related to Strongbridge Biopharma include Cara Therapeutics (CARA), Retrophin (RTRX), Akero Therapeutics (AKRO), Vanda Pharmaceuticals (VNDA), TherapeuticsMD (TXMD), BioXcel Therapeutics (BTAI), Emisphere Technologies (EMIS), Aprea Therapeutics (APRE), RAPT Therapeutics (RAPT), Omeros (OMER), Vectura Group (VEGPF), Basilea Pharmaceutica (BPMUF), Flexion Therapeutics (FLXN), XBiotech (XBIT) and Phoenix Tree (IMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include Energy Transfer LP Unit (ET), Genocea Biosciences (GNCA), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Opko Health (OPK), Abeona Therapeutics (ABEO), Sorrento Therapeutics (SRNE) and Ovid Therapeutics (OVID).

Strongbridge Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.25%), Point72 Asset Management L.P. (1.20%), Renaissance Technologies LLC (1.18%), Diversified Trust Co (0.37%), Alambic Investment Management L.P. (0.22%) and Private Advisors LLC (0.14%). View Institutional Ownership Trends for Strongbridge Biopharma.

SBBP stock was sold by a variety of institutional investors in the last quarter, including Private Advisors LLC and Tredje AP fonden. View Insider Buying and Selling for Strongbridge Biopharma.

SBBP stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Diversified Trust Co, Point72 Asset Management L.P., Alambic Investment Management L.P., Bank of Montreal Can, State Street Corp, Acadian Asset Management LLC and Panagora Asset Management Inc.. View Insider Buying and Selling for Strongbridge Biopharma.

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBBP stock can currently be purchased for approximately $3.39.

Strongbridge Biopharma has a market capitalization of $183.76 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]